혈액암 (AML/ALL) · DLL3

4개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved4 programs
AntibodyCurated CoreFDAAmgenApproved

tarlatamab (Imdelltra, AMG 757, tarlatamab-dlle)

Extensive-stage small cell lung cancer after platinum-based chemotherapy · DLL3 × CD3

#DLL3CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 39Status Approved
CGTLimited DatastaleBeijing BiotechPhase 2

DLL3-CAR-NK cells (DLL3-CAR-NK cells)

Extensive Stage Lung Small Cell Cancer · SCLC, Extensive Stage

#SCLCExtensiveStage#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 4Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

BHP01 (α-PD-L1/4-1BB DLL3 CAR-T, α-PD-L1/4-1BB DLL3 CAR-T (BHP01))

Small Cell Lung Cancer Extensive Stage · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting